Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YRJDY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HM2- MMAE
|
|||||
| Synonyms |
ALT P7; ALT-P7; ALT-P7 (HM2- MMAE); HM2-MMAE; HM2-drug conjugate
Click to Show/Hide
|
|||||
| Organization |
Alteogen, Inc.; Shenyang Sunshine Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Trastuzumab variant
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Drugbank ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
13.3% (4.2 mg/kg)
|
|||
| Patients Enrolled |
Patients with HER2-positive advanced breast cancer progressive to at least two kinds of prior anti-HER2 treatment.
|
||||
| Administration Dosage |
0.30-4.80 mg/kg iv administered once every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03281824 | Clinical Status | Phase 1 | ||
| Clinical Description | Open-label, dose increase and phase 1 study of ALT-P7 to determine safety, tolerability, pharmacokinetics for HER2 positive metastatic breast cancer patients who have progressed on previous trastuzumab-based therapy. | ||||
References